Importer of Controlled Substances Application: Cardinal Health, 35664 [2020-12625]
Download as PDF
<![CDATA[
35664
Federal Register / Vol. 85, No. 113 / Thursday, June 11, 2020 / Notices
regarding filing should contact the
Secretary (202–205–2000).
Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment. All such requests should be
directed to the Secretary to the
Commission and must include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All information,
including confidential business
information and documents for which
confidential treatment is properly
sought, submitted to the Commission for
purposes of this Investigation may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel,1 solely for cybersecurity
purposes. All non-confidential written
submissions will be available for public
inspection at the Office of the Secretary
and on EDIS.
The Commission vote for these
determinations took place on June 5,
2020.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in Part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
[FR Doc. C1–2020–10601 Filed 6–10–20; 8:45 am]
Drug Enforcement Administration
[Docket No. DEA–663]
Importer of Controlled Substances
Application: Cardinal Health
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 13, 2020. Such persons
may also file a written request for a
hearing on the application on or before
July 13, 2020.
DATES:
ADDRESSES:
Controlled substance
Drug
code
Schedule
Correction
In notice document 2020–10601,
appearing on pages 29741 through
1 All
contract personnel will sign appropriate
nondisclosure agreements.
VerDate Sep<11>2014
17:33 Jun 10, 2020
Jkt 250001
Agency Information Collection
Activities; Proposed eCollection;
eComments Requested; Extension
Without Change of Previously
Approved Collection OJP Solicitation
Template
Office of Justice Programs,
Department of Justice.
ACTION: 60-Day notice.
Notice of application.
In
accordance with 21 CFR 1301.34(a), this
is notice that on June 1, 2020, Cardinal
Health, 15 Ingram Boulevard, La Vergne,
Tennessee 37086–3630, applied to be
registered as an importer of the
following basic class(es) of controlled
substance:
Bulk Manufacturer of Controlled
Substances Application: SpecGx LLC
BILLING CODE 4410–09–P
AGENCY:
ACTION:
SUPPLEMENTARY INFORMATION:
[Docket No. DEA–610]
[FR Doc. 2020–12625 Filed 6–10–20; 8:45 am]
[OMB Number 1121–0329]
DEPARTMENT OF JUSTICE
BILLING CODE 7020–02–P
Drug Enforcement Administration
William T. McDermott,
Assistant Administrator.
DEPARTMENT OF JUSTICE
[FR Doc. 2020–12594 Filed 6–10–20; 8:45 am]
DEPARTMENT OF JUSTICE
registrants for the purpose of medical
use only.
BILLING CODE 1300–01–D
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
By order of the Commission.
Issued: June 5, 2020.
Lisa Barton,
Secretary to the Commission.
jbell on DSKJLSW7X2PROD with NOTICES
29742 in the issue of Monday, May 18,
2020 make the following correction.
On page 29741, in the third column,
in the DATES section, on the last line,
‘‘July 17, 2025’’ should read ‘‘July 17,
2020’’.
Secobarbitol ..................
2315
II
The company plans to import the
above controlled substance in finished
dosage form for distribution to licensed
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
The Department of Justice
(DOJ), Office of Justice Programs (OJP),
will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until
August 10, 2020.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Jennifer Yeh, (202) 616–9135, Office of
Audit, Assessment, and Management,
Office of Justice Programs, U.S.
Department of Justice, 810 Seventh
Street NW, Washington, DC 20531 or
Jennifer.Yeh2@usdoj.gov.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the Office of Justice
Programs, including whether the
information will have practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
SUMMARY:
E:\FR\FM\11JNN1.SGM
11JNN1
]]>Agencies
[Federal Register Volume 85, Number 113 (Thursday, June 11, 2020)]
[Notices]
[Page 35664]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-12625]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-663]
Importer of Controlled Substances Application: Cardinal Health
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before July 13, 2020.
Such persons may also file a written request for a hearing on the
application on or before July 13, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on June 1, 2020, Cardinal Health, 15 Ingram Boulevard,
La Vergne, Tennessee 37086-3630, applied to be registered as an
importer of the following basic class(es) of controlled substance:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Secobarbitol........................... 2315 II
------------------------------------------------------------------------
The company plans to import the above controlled substance in
finished dosage form for distribution to licensed registrants for the
purpose of medical use only.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-12625 Filed 6-10-20; 8:45 am]
BILLING CODE 4410-09-P
